View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2013	Jul. 29, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 28, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	exel
Entity Registrant Name	EXELIXIS, INC.
Entity Central Index Key	0000939767
Entity Filer Category	Large Accelerated Filer
Current Fiscal Year End Date	--12-27
Entity Common Stock, Shares Outstanding		184,117,209

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
ASSETS
Cash and cash equivalents	$ 131,774	$ 170,069
Short-term Investments	220,198	241,371
Short-term restricted cash and investments	12,214	12,246
Trade and other receivables	4,209	2,751
Inventory	681	0
Prepaid expenses and other current assets	5,880	6,104
Total current assets	374,956	432,541
Long-term investments	138,125	182,311
Long-term restricted cash and investments	21,956	27,964
Property and equipment, net	5,650	6,059
Goodwill	63,684	63,684
Other assets	7,713	8,538
Total assets	612,084	721,097
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	3,458	4,398
Accrued clinical trial liabilities	29,406	20,560
Accrued compensation and benefits	8,127	10,375
Other accrued liabilities	15,362	11,795
Current portion of convertible notes	10,000	10,000
Current portion of loans payable	2,546	3,170
Current portion of restructuring	4,194	5,085
Deferred revenue	1,507	16,321
Total current liabilities	74,600	81,704
Long-term portion of convertible notes	242,459	240,476
Long-term portion of loans payable	81,132	82,090
Long-term portion of restructuring	11,679	14,137
Other long-term liabilities	5,882	6,256
Total liabilities	415,752	424,663
Contingencies (Note 9)
Stockholders' Equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued	0	0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 184,104,277 and 183,697,213 shares at June 30, 2013 and December 31, 2012, respectively	184	183
Additional paid-in capital	1,557,303	1,550,345
Accumulated other comprehensive loss	(263)	(92)
Accumulated deficit	(1,360,892)	(1,254,002)
Total stockholders’ equity	196,332	296,434
Total liabilities and stockholders' equity	$ 612,084	$ 721,097

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Preferred stock, par value, in dollars per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value, in dollars per share	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	184,104,277	183,697,213
Common stock, shares outstanding	184,104,277	183,697,213

Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
License and contract revenues	$ 7,813	$ 7,813	$ 15,626	$ 26,323
Net product revenues	4,043	0	5,899	0
Total revenues	11,856	7,813	21,525	26,323
Operating expenses:
Cost of goods sold	285	0	565	0
Research and development	49,077	32,610	81,812	65,706
Selling, general and administrative	13,180	6,760	23,725	14,665
Restructuring charge	609	1,166	728	971
Total operating expenses	63,151	40,536	106,830	81,342
Loss from operations	(51,295)	(32,723)	(85,305)	(55,019)
Other income (expense), net:
Interest income and other, net	373	340	711	500
Interest expense	(11,239)	(4,092)	(22,296)	(8,096)
Total other income (expense), net	(10,866)	(3,752)	(21,585)	(7,596)
Loss before income taxes	(62,161)	(36,475)	(106,890)	(62,615)
Income tax provision	0	12	0	23
Net loss	$ (62,161)	$ (36,487)	$ (106,890)	$ (62,638)
Net loss per share, basic and diluted, in dollars per share	$ (0.34)	$ (0.25)	$ (0.58)	$ (0.43)
Shares used in computing basic and diluted net loss per share, in shares	183,981	148,654	183,861	145,297

Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2013

Jun. 30, 2012

Statement of Comprehensive Income [Abstract]

Net loss

$ (62,161)

$ (36,487)

$ (106,890)

$ (62,638)

Other comprehensive income (loss)

^[1]

(365)

(45)

(171)

143

Comprehensive loss

$ (62,526)

$ (36,532)

$ (107,061)

$ (62,495)

[1]

Other comprehensive income (loss) consisted solely of unrealized gains or losses on available for sale securities arising during the periods presented. There were no reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income during those periods.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Statement of Cash Flows [Abstract]
Net loss	$ (106,890)	$ (62,638)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,628	2,640
Stock-based compensation expense	5,605	4,322
Restructuring credit for property and equipment	0	(179)
Accretion of debt discount	12,793	4,477
Other	3,642	2,366
Changes in assets and liabilities:
Other receivables	(1,458)	27,506
Inventory	(681)	0
Prepaid expenses and other current assets	224	(254)
Other assets	0	(224)
Accounts payable and other accrued liabilities	379	(2,058)
Clinical trial liability	8,846	2,259
Restructuring liability	(3,349)	(1,995)
Other long-term liabilities	(374)	(286)
Deferred revenue	(14,814)	(26,293)
Net cash used in operating activities	(94,449)	(50,357)
Cash flows from investing activities:
Purchases of property and equipment	(1,402)	(509)
Proceeds from sale of property and equipment	0	859
Proceeds from maturities of restricted cash and investments	9,868	0
Purchase of restricted cash and investments	(3,784)	132
Proceeds from maturities of investments	209,889	141,104
Purchases of investments	(147,751)	(160,221)
Net cash provided by (used in) investing activities	66,820	(18,635)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	0	65,036
Proceeds from exercise of stock options and warrants	22	306
Proceeds from employee stock purchase plan	894	827
Principal payments on debt	(11,582)	(3,294)
Net cash (used in) provided by financing activities	(10,666)	62,875
Net decrease in cash and cash equivalents	(38,295)	(6,117)
Cash and cash equivalents, at beginning of period	170,069	74,257
Cash and cash equivalents, at end of period	$ 131,774	$ 68,140

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Exelixis, Inc. (“Exelixis,” “we,” “our” or “us”) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. We are focusing our proprietary resources and development and commercialization efforts exclusively on COMETRIQ^® (cabozantinib), our wholly-owned inhibitor of multiple receptor tyrosine kinases. On November 29, 2012, the U.S. Food and Drug Administration approved COMETRIQ for the treatment of progressive, metastatic medullary thyroid cancer (“MTC”), in the United States, where it became commercially available in late January 2013. Cabozantinib is being evaluated in a variety of other cancer indications through a broad development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer, a phase 3 pivotal trial in metastatic renal cell cancer and an additional phase 3 pivotal trail in metastatic hepatocellular cancer that we plan to initiate later in 2013. We believe COMETRIQ has the potential to be a high-quality, broadly-active and differentiated anti-cancer agent that can make a meaningful difference in the lives of patients. Our objective is to develop COMETRIQ into a major oncology franchise, and we believe that the approval of COMETRIQ for the treatment of progressive, metastatic MTC provides us with the opportunity to establish a commercial presence in furtherance of this objective. We have also established a portfolio of other novel compounds that we believe have the potential to address serious unmet medical needs. Many of these compounds are being developed by partners as part of collaborations, at no cost to us but with significant retained economics to us in the event these compounds are commercialized. As disclosed on ClinicalTrials.gov (NCT01689519), a phase 3 clinical trial for one of these compounds, cobimetinib (GDC-0973/XL518), which we out-licensed to Genentech, Inc. (a wholly-owned member of the Roche Group), was initiated on November 1, 2012. Basis of Consolidation The consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the period presented have been included. Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31^st. Fiscal year 2012, a 52-week year, ended on December 28, 2012, and fiscal year 2013, a 52-week year, will end on December 27, 2013. For convenience, references in this report as of and for the fiscal quarters ended June 29, 2012 and June 28, 2013, and as of the fiscal year ended December 28, 2012, are indicated as ended June 30, 2012, June 30, 2013, and December 31, 2012, respectively. Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013 or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2012, included in our Annual Report on Form 10-K filed with the SEC on February 21, 2013. Segment Information We operate in one business segment. We have operations primarily in the United States, while some of our collaboration partners have headquarters outside of the United States and certain of our clinical trials for cabozantinib are conducted outside of the United States. In fiscal years 2011 and 2012, 100% of our revenues were earned in the United States. During the three months ended June 30, 2013, we initiated a Named Patient Use Program (“NPU”) through our distribution partner Swedish Orphan Biovitrum (“Sobi”) to support the distribution and commercialization of COMETRIQ for metastatic MTC primarily in the European Union and potentially other countries. During the three and six months ended June 30, 2013, 93% and 95% of our revenues were earned in the United States; the remainder of our revenues were earned in the European Union under this NPU program. All of our long-lived assets are located in the United States. Use of Estimates The preparation of the consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, inventory valuation, valuation of long-lived assets, certain accrued liabilities, share-based compensation and the valuation of the debt and equity components of our convertible debt at issuance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Inventory We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but rather are expensed as research and development costs. When regulatory approval is obtained, we begin capitalization of inventory related costs. We received regulatory approval for our first product, COMETRIQ, on November 29, 2012. Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations. Goodwill Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value, by applying the purchase method. Goodwill is not subject to amortization. We evaluate goodwill for impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired. When evaluating goodwill for impairment we must determine the reporting units that exist within Exelixis. We have determined that we have one reporting unit, which is consistent with our sole operating segment as of June 30, 2013 and December 31, 2012. Revenue Recognition We recognize revenue from the sale of COMETRIQ and from license fees and milestones earned on research and collaboration arrangements. See “Note 1 - Organization and Summary of Significant Accounting Policies” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a description of our policies for revenue recognition on research and collaboration agreements. We did not enter into any new collaboration agreements during the three and six months ended June 30, 2013. See “Note 2 - Research and Collaboration Agreements” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a description of our existing collaboration agreements. Net Product Revenues We recognize revenue when it is both realized or realizable and earned, meaning persuasive evidence of an arrangement exists, delivery has occurred, title has transferred, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured. For product sales in the United States, this generally occurs upon shipment of the product to the patient. For product sales in Europe, this occurs when our distribution partner, Sobi, has accepted the product. We sell our product, COMETRIQ, in the United States to a specialty pharmacy that benefits from customer incentives and has a right of return. We have a limited sales history and cannot reliably estimate expected returns of the product nor the discounts and rebates due to payors at the time of shipment to the specialty pharmacy. Accordingly, upon shipment to the specialty pharmacy, we record deferred revenue on our Consolidated Balance Sheets. We recognize revenue when the specialty pharmacy provides the product to a patient based on the fulfillment of a prescription. We record revenue using an analysis of prescription data from our specialty pharmacy to ascertain the date of shipment and the payor mix. This approach is frequently referred to as the “sell-through” revenue recognition model. Once the prescription has been provided to the patient, it is not subject to return unless the product is damaged. Product sales to Sobi are not subject to customer incentives, rights of return or discounts and allowances. We record revenue at the time Sobi has accepted the product, a method also known as the “sell-in” revenue recognition model. Product Sales Discounts and Allowances We calculate gross product revenues based on the price that we charge our United States specialty pharmacy and our European distribution partner, Sobi. We estimate our net product revenues by deducting from our gross product revenues (a) trade allowances, such as discounts for prompt payment, (b) estimated government rebates and chargebacks, and (c) estimated costs of patient assistance programs. We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. These discounts and allowances apply only to gross product revenues earned in the United States. Customer Credits: The United States specialty pharmacy receives a discount of 2% for prompt payment. We expect this specialty pharmacy will earn 100% of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Mandated Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payor data received from the United States specialty pharmacy. Rebates are generally invoiced by the payor and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s shipments to patients, plus an accrual balance for known prior quarter’s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment. Chargebacks: Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The United States specialty pharmacy, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on sales to contracted customers. Medicare Part D Coverage Gap: In the United States, the Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part D coverage gap are based in part on third party market research data and on customer and payor, data received from the United States specialty pharmacy. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment. Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by our United States specialty pharmacy. Patient Assistance Program We provide COMETRIQ at no cost to eligible patients who have no insurance or are otherwise unable to pay for our product through our Patient Assistance Program (“PAP”). We record the cost of the product as a selling, general and administrative expense at the time the product is designated as PAP inventory. Cost of Goods Sold Cost of goods sold is related to our product revenues and consists primarily of indirect labor costs, a 3% royalty we are required to pay GlaxoSmithKline and direct logistics costs. A significant portion of the manufacturing costs for current product sales were incurred prior to regulatory approval of COMETRIQ for the treatment of progressive, metastatic MTC and, therefore, are expensed as research and development costs as incurred, rather than capitalized as inventory. In accordance with our 2002 collaboration agreement with GlaxoSmithKline, we are required to pay GlaxoSmithKline a 3% royalty on the Net Sales of any product incorporating cabozantinib, including COMETRIQ. Net Sales is defined in the collaboration agreement generally as the gross invoiced sales price less customer credits, rebates, chargebacks, shipping costs, customs duties, and sales tax and other similar tax payments we are required to make. Recently Adopted Accounting Pronouncements In February 2013, Accounting Standards Codification Topic 220, Comprehensive Income was amended to require additional information about amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning January 1, 2013, and will provide the additional information when such reclassifications occur. The amendment did not have a material effect on our consolidated financial statements.

Restructurings

6 Months Ended

Jun. 30, 2013

Restructuring Charges [Abstract]

Restructurings

RESTRUCTURINGS

In May 2013, we implemented the last of a series of five restructurings which commenced in March 2010 (referred to as the “Restructurings”) as a consequence of our decision to focus our proprietary resources and development efforts on the development and commercialization of cabozantinib and strategy to manage costs. The restructuring implemented in May 2013 related to the termination of drug discovery personnel following the completion of our obligations under our ROR collaboration agreement with Bristol-Myers Squibb. The aggregate reduction in headcount from the Restructurings was 429 employees. Charges and credits related to the Restructurings were recorded in periods other than those in which the Restructurings were implemented as a result of sublease activities for our buildings in South San Francisco, California, changes in assumptions regarding anticipated sublease activities, the effect of the passage of time on our discounted cash flow computations, previously planned employee terminations, and sales of excess equipment and other assets.

We have recorded aggregate restructuring charges of $52.8 million in connection with the Restructurings, of which $21.5 million related to termination benefits, $29.0 million related to facility charges, $2.2 million net related to the impairment of excess equipment and other assets, and $0.1 million related to legal and other fees. Asset impairment charges, net were partially offset by cash proceeds of $2.6 million from the sale of such assets.

For the six months ended June 30, 2013 and 2012, we recorded restructuring charges of $0.7 million and $1.0 million, respectively, which related to termination benefits and facility charges in connection with the exit of portions of three of our buildings in South San Francisco.

The total outstanding restructuring liability related to the Restructurings is included in current and long-term portion of restructuring on our Consolidated Balance Sheets. The components and changes of these liabilities during the six months ended June 30, 2013 and for the period from inception of the restructuring activities through the year ended December 31, 2012 are summarized in the following table (in thousands):



	Employee Severance And Other Benefits			Facility Charges			Asset Impairment			Legal and Other Fees			Total
Restructuring (credit) charge	$	17,677		$	11,814		$	3,173		$	80		$	32,744
Cash payments	(10,528		)	(3,739		)	—			(10		)	(14,277		)
Adjustments or non-cash credits	(1,626		)	613			(3,341		)	—			(4,354		)
Proceeds from sale of assets	—			—			168			—			168
Restructuring liability as of December 31, 2010	5,523			8,688			—			70			14,281
Restructuring (credit) charge	2,566			8,480			(907		)	(3		)	10,136
Cash payments	(7,366		)	(3,469		)	—			(16		)	(10,851		)
Adjustments or non-cash credits	(717		)	222			(619		)	—			(1,114		)
Proceeds from sale of assets	—			—			1,526			—			1,526
Restructuring liability as of December 31, 2011	6			13,921			—			51			13,978
Restructuring (credit) charge	970			8,276			(47		)	(28		)	9,171
Cash payments	(965		)	(5,299		)	—			(3		)	(6,267		)
Adjustments or non-cash credits including stock compensation expense	(11		)	2,304			(891		)	—			1,402
Proceeds from sale of assets	—			—			938			—			938
Restructuring liability as of December 31, 2012	—			19,202			—			20			19,222
Restructuring charge	263			465			—			—			728
Cash payments	—			(3,955		)	—			—			(3,955		)
Adjustments or non-cash credits	(49		)	(73		)	—			—			(122		)
Restructuring liability as of June 30, 2013	$	214		$	15,639		$	—		$	20		$	15,873

We expect to pay accrued facility charges of $15.6 million, net of cash received from our subtenants, through 2017, or the end of our lease terms of the buildings. With respect to our Restructurings, we expect to incur additional restructuring charges of approximately $2.5 million, of which approximately $0.3 million relate to termination benefits. with the balance relating to the exit of certain of our South San Francisco buildings. These charges will be recorded through the end the building lease terms, the latest of which ends in 2017.

The Restructurings have resulted in aggregate cash expenditures of $32.7 million, net of sublease income and net of $2.6 million in cash received in connection with the sale of excess equipment and other assets. Net cash expenditures for the Restructurings were $1.5 million and $1.3 million during the three months ended June 30, 2013, and 2012, respectively and $4.0 million and $2.3 million during the six months ended June 30, 2013 and 2012, respectively.

The restructuring charges that we expect to incur in connection with the Restructurings are subject to a number of assumptions, and actual results may materially differ. We may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, the Restructurings.

Cash and Investments

6 Months Ended

Jun. 30, 2013

Investments, Debt and Equity Securities [Abstract]

Cash and Investments

CASH AND INVESTMENTS

The following table summarizes cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of June 30, 2013 and December 31, 2012 (in thousands):



	June 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
As reported:
Cash and cash equivalents	$	131,773	$	1	$	—		$	131,774
Short-term investments	220,254		62		(118		)	220,198
Short-term restricted cash and investments	12,193		21		—			12,214
Long-term investments	138,400		7		(282		)	138,125
Long-term restricted cash and investments	21,910		46		—			21,956
Total cash and investments	$	524,530	$	137	$	(400	)	$	524,267



	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
As reported:
Cash and cash equivalents	$	170,070	$	—	$	(1	)	$	170,069
Short-term investments	241,391		46		(66		)	241,371
Short-term restricted cash and investments	12,242		4		—			12,246
Long-term investments	182,407		28		(124		)	182,311
Long-term restricted cash and investments	27,943		21		—			27,964
Total cash and investments	$	634,053	$	99	$	(191	)	$	633,961

Under our loan and security agreement with Silicon Valley Bank, we are required to maintain compensating balances on deposit in one or more investment accounts with Silicon Valley Bank and certain other designated financial institutions. The total collateral balances as of June 30, 2013 and December 31, 2012 were $85.4 million and $87.0 million, respectively, and are reflected in our Consolidated Balance Sheets in short- and long-term investments. See “Note 7 - Debt” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012, for more information regarding the collateral balance requirements under our Silicon Valley Bank loan and security agreement.

All of our cash equivalents and investments are classified as available-for-sale. The following table summarizes our cash equivalents and investments by security type as of June 30, 2013 and December 31, 2012 (in thousands):



	June 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Cash and money market funds	$	62,054	$	—	$	—		$	62,054
Commercial paper	87,217		—		(2		)	87,215
Corporate bonds	273,748		42		(396		)	273,394
U.S. Treasury and government sponsored enterprises	89,493		94		—			89,587
Municipal bonds	12,018		1		(2		)	12,017
Total cash and investments	$	524,530	$	137	$	(400	)	$	524,267



	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Cash and money market funds	$	81,744	$	2	$	—		$	81,746
Commercial paper	167,223		8		—			167,231
Corporate bonds	222,106		30		(187		)	221,949
U.S. Treasury and government sponsored enterprises	132,933		59		(1		)	132,991
Municipal bonds	30,047		—		(3		)	30,044
Total cash and investments	$	634,053	$	99	$	(191	)	$	633,961

All of our investments are subject to a quarterly impairment review. During the three and six months ended June 30, 2013 and 2012, we did not record any other-than-temporary impairment charges on our available-for-sale securities. As of June 30, 2013, the fair value of investments that were in an unrealized loss position was $223.3 million, including $215.2 million in corporate bonds. There were 104 investments in an unrealized loss position as of June 30, 2013. All investments in an unrealized loss position have been so for less than one year and the unrealized losses were not attributed to credit risk, but rather associated with the changes in interest rates. Based on the scheduled maturities of our investments, we concluded that the unrealized losses in our investment securities are not other-than-temporary, as it is more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.

The following summarizes the fair value of securities classified as available-for-sale by contractual maturity as of June 30, 2013 (in thousands):



	Mature within One Year		After One Year through Two Years		Fair Value
Money market funds	$	58,934	$	—	$	58,934
Commercial paper	87,215		—		87,215
Corporate bonds	176,441		96,953		273,394
U.S. Treasury and government sponsored enterprises	71,357		18,230		89,587
Municipal bonds	12,017		—		12,017
Total	$	405,964	$	115,183	$	521,147

The classification of certain compensating balances and restricted investments are dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. Therefore, certain long-term investments and long-term restricted cash and investments have contractual maturities within one year.

During the three and six months ended June 30, 2013 and 2012, there were no sales of investments, and therefore there were no reclassification adjustments of accumulated other comprehensive income to net income resulting from realized gains or losses on the sale of securities.

Inventory

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Inventory

INVENTORY

Inventory consists of the following (in thousands):



	June 30, 2013		December 31, 2012
Raw materials	$	75	$	—
Work in process	537		—
Finished goods	69		—
Total	$	681	$	—

We received regulatory approval for our first product, COMETRIQ, on November 29, 2012. As of December 31, 2012, our recorded inventory balance was $0 as we did not incur any costs that would be recorded as inventory subsequent to the receipt of regulatory approval and prior to year end.

Debt

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Debt

DEBT

The amortized carrying amount of our debt consists of the following (in thousands):



	June 30, 2013			December 31, 2012
Convertible Senior Subordinated Notes due 2019	$	157,357		$	149,800
Secured Convertible Notes due 2015	95,102			100,676
Silicon Valley Bank term loan	80,000			80,000
Silicon Valley Bank line of credit	3,678			5,260
Total debt	336,137			335,736
Less: current portion	(12,546		)	(13,170		)
Long-term debt	$	323,591		$	322,566

See “Note 7 - Debt” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012, for additional information on the terms of our debt, including a description of the conversion features of the of 4.25% convertible senior subordinated notes due 2019 (the “2019 Notes”) and our Secured Convertible Notes due June 2015 (the “Deerfield Notes”).

Convertible Senior Subordinated Notes due 2019

In August 2012, we issued and sold $287.5 million aggregate principal amount the 2019 Notes. As of June 30, 2013, the entire principal balance remains outstanding. The following is a summary of the liability component of the 2019 Notes as of June 30, 2013 (in thousands):



	June 30, 2013
Net carrying amount of the liability component	$	157,357
Unamortized discount of the liability component	130,143
Face amount of the 2019 Notes	$	287,500

The debt discount and debt issuance costs will be amortized as interest expense through August 2019. During the three and six months ended June 30, 2013, total interest expense for the 2019 Notes was $7.1 million, and $14.0 million, respectively, including stated coupon interest of $3.1 million and $6.1 million, respectively, and the amortization of the debt discount and debt issuance costs of $4.0 million and $7.9 million, respectively. The balance of unamortized fees and costs was $4.3 million and $4.7 million as of June 30, 2013, and December 31, 2012, respectively, which is recorded in the accompanying Consolidated Balance Sheet as Other assets.

Secured Convertible Notes due June 2015

In June 2010, we entered into a note purchase agreement with entities affiliated with Deerfield Management Company, L.P. (“Deerfield”), pursuant to which, on July 1, 2010, we sold to Deerfield an aggregate of $124.0 million initial principal amount of the Deerfield Notes. As of June 30, 2013, and December 31, 2012, the remaining outstanding principal balance on the Deerfield Notes was $114.0 million and $124.0 million, respectively. During the three and six months ended June 30, 2013, total interest expense for the Deerfield Notes was $4.0 million and $7.9 million, respectively, and during the same periods in 2012, $3.9 million and $7.7 million, respectively, including the stated coupon rate and the amortization of the debt discount and debt issuance costs. The non-cash expense relating to the amortization of the debt discount and debt issuance costs were $2.5 million and $4.9 million during the three and six months ended June 30, 2013, respectively, and $2.4 million and $4.7 million, during the three and six months ended June 30, 2012, respectively. The balance of unamortized fees and costs was $1.8 million and $2.3 million as of June 30, 2013, and December 31, 2012, respectively, which is recorded in the accompanying Consolidated Balance Sheet as Other assets.

Fair Value Measurements

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

The fair value of our financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy has the following three levels:

Level 1 – quoted prices in active markets for identical assets and liabilities.

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets.

Level 3—unobservable inputs.

A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy. There were no transfers between any of the fair value hierarchies, as determined at the end of each reporting period.

The following table sets forth the fair value of our financial assets that were measured and recorded on a recurring basis as of June 30, 2013 and December 31, 2012. We did not have any Level 3 investments during the periods presented. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):



	June 30, 2013
	Level 1		Level 2		Total
Money market funds	$	58,934	$	—	$	58,934
Commercial paper	2,997		84,218		87,215
Corporate bonds	7,013		266,381		273,394
U.S. Treasury and government sponsored enterprises	30,444		59,143		89,587
Municipal bonds	—		12,017		12,017
Total	$	99,388	$	421,759	$	521,147



	December 31, 2012
	Level 1		Level 2		Total
Money market funds	$	76,050	$	—	$	76,050
Commercial paper	—		167,231		167,231
Corporate bonds	—		221,949		221,949
U.S. Treasury and government sponsored enterprises	—		132,991		132,991
Municipal bonds	—		30,044		30,044
Total	$	76,050	$	552,215	$	628,265

The estimated fair values of our financial instruments that are carried at amortized cost for which it is practicable to determine a fair value were as follows (in thousands):



	June 30, 2013				December 31, 2012
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Convertible Senior Subordinated Notes due 2019	$	157,357	$	279,939	$	149,800	$	280,111
Silicon Valley Bank term loan	$	80,000	$	79,767	$	80,000	$	79,542
Silicon Valley Bank Line of Credit	$	3,678	$	3,676	$	5,260	$	5,253

There is no practicable method to determine the fair value of the Deerfield Notes due to the unique structure of the instrument that was financed by entities affiliated with Deerfield and the current non-liquid market in structured notes. The carrying amounts of cash, trade and other receivables, accounts payable and accrued clinical trial liabilities approximate their fair values and are excluded from the tables above.

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate a value:


•	When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing, which is a Level 2 input.


•	2019 Notes are valued using a third-party pricing model that is based in part on average trading prices, which is a Level 2 input. The 2019 Notes are not marked-to-market and are shown at their initial fair value less the unamortized discount; the portion of the value allocated to the conversion option is included in Stockholders’ equity in the accompanying Consolidated Balance Sheets.


•	We have estimated the fair value of our other debt instruments, where possible, using the net present value of the payments discounted at an interest rate that is consistent with money-market rates that would have been earned on our non-interest-bearing compensating balances, which is a Level 2 input.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stock-Based Compensation

6 Months Ended

Jun. 30, 2013

Share-based Compensation [Abstract]

Stock-Based Compensation

STOCK-BASED COMPENSATION

We recorded and allocated employee stock-based compensation expenses for our equity incentive plans and our 2000 Employee Stock Option Plan (“ESPP”) as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development expense	$	1,553	$	1,025	$	2,960	$	2,232
Selling, general and administrative expense	1,370		950		2,638		2,047
Total employee stock-based compensation expense	$	2,923	$	1,975	$	5,598	$	4,279

We use the Black-Scholes option pricing model to value our stock options. The expected life computation is based on historical exercise patterns and post-vesting termination behavior. We considered implied volatility as well as our historical volatility in developing our estimate of expected volatility. The fair value of employee stock option awards and ESPP purchases was estimated using the following assumptions and weighted average fair values:



	Stock Options
	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Weighted average grant-date fair value	$	2.56		$	2.68		$	2.52		$	2.75
Risk-free interest rate	0.98		%	1.00		%	0.92		%	1.00		%
Dividend yield	—		%	—		%	—		%	—		%
Volatility	62		%	65		%	62		%	65		%
Expected life	5.6 years			6.0 years			5.5 years			5.8 years



	Employee Stock Purchase Plan
	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Weighted average grant-date fair value	$	1.65		$	1.58		$	1.63		$	2.34
Risk-free interest rate	0.12		%	0.16		%	0.13		%	0.08		%
Dividend yield	—		%	—		%	—		%	—		%
Volatility	67		%	68		%	67		%	68		%
Expected life	0.5 years			0.5 years			0.5 years			0.5 years

755,792 of the stock options outstanding as of June 30, 2013, were granted subject to performance objectives tied to the achievement of clinical goals set by the Compensation Committee of our Board of Directors and will vest in full or part based on achievement of such goals. As of June 30, 2013, we expect that achievement of those performance objectives is probable.

A summary of all stock option activity for the six months ended June 30, 2013 is presented below (dollars in thousands, except per share amounts):



	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2012	18,448,550		$	6.85
Granted	851,130		$	4.65
Exercised	(3,884	)	$	4.42
Forfeited	(586,964	)	$	6.47
Options outstanding at June 30, 2013	18,708,832		$	6.76	4.35	$	108
Exercisable at June 30, 2013	13,175,393		$	7.31	3.63	$	94

As of June 30, 2013, $13.6 million of total unrecognized compensation expense related to employee stock options was expected to be recognized over a weighted-average period of 2.64 years.

A summary of all restricted stock unit (“RSU”) activity for the six months ended June 30, 2013 is presented below (dollars in thousands, except per share amounts):



	Shares		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Awards outstanding at December 31, 2012	1,294,621		$	6.07
Awarded	87,710		$	4.74
Released	(153,747	)	$	7.34
Forfeited	(15,208	)	$	5.74
Awards outstanding at June 30, 2013	1,213,376		$	5.82	1.55	$	5,509

As of June 30, 2013, $4.9 million of total unrecognized compensation expense related to employee RSUs was expected to be recognized over a weighted-average period of 2.73 years.

Net Loss Per Share

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Net Loss Per Share

NET LOSS PER SHARE

The following table sets forth a reconciliation of basic and diluted net loss per share (in thousands, except per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Numerator:
Net loss	$	(62,161	)	$	(36,487	)	$	(106,890	)	$	(62,638	)
Denominator:
Shares used in computing basic and diluted net loss per share	183,981			148,654			183,861			145,297
Net loss per share, basic and diluted	$	(0.34	)	$	(0.25	)	$	(0.58	)	$	(0.43	)

Diluted loss income per share gives effect to potential incremental common shares issuable upon the exercise of stock options and warrants, upon vesting of RSUs, upon the purchase from contributions to our ESPP (all calculated based on the treasury stock method), and upon conversion of our convertible debt (calculated using the if-converted method) and the effect is not anti-dilutive. The following table sets forth potential shares of common stock that are not included in the computation of diluted net loss per share because, to do so would be anti-dilutive (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2013	2012	2013	2012
Convertible debt	54,123	—	54,123	—
Outstanding stock options, unvested RSUs and ESPP contributions	18,147	17,477	18,007	16,226
Warrants	1,441	1,441	1,441	1,441
Total potentially dilutive shares	73,711	18,918	73,571	17,667

Contingencies	6 Months Ended
Contingencies	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES Pending Litigation From time to time, we are party to legal proceedings, claims and investigations in the ordinary course of business, including the matter described below. In December 2012, a former officer filed a lawsuit against us and our chief executive officer in California state court seeking unspecified monetary damages based on contract and tort claims in connection with the former officer’s execution and revocation of a Rule 10b5-1 stock trading plan in December 2010. We intend to defend this claim vigorously. This matter is at a early stage, and we are unable to reasonably estimate the possible loss or range of loss, if any.

Concentrations of Credit Risk

6 Months Ended

Jun. 30, 2013

Risks and Uncertainties [Abstract]

Concentrations of Credit Risk

CONCENTRATIONS OF CREDIT RISK

Financial instruments that potentially subject us to concentrations of credit risk are primarily trade and other receivables and investments. Investments consist of money market funds, taxable commercial paper, corporate bonds with high credit quality, U.S. government agency obligations and U.S. government sponsored enterprises. All investments are maintained with financial institutions that management believes are creditworthy.

Trade and other receivables are unsecured and are concentrated in the pharmaceutical and biotechnology industries. Accordingly, we may be exposed to credit risk generally associated with pharmaceutical and biotechnology companies. We have incurred no bad debt expense since inception. Currently, 71% of our trade receivables are with the United States specialty pharmacy that sells COMETRIQ.

The following table sets forth the percentage of revenues recognized under our collaboration agreements and product sales to the specialty pharmacy that represent 10% or more of total revenues during the six months ending June 30, 2013 and 2012:



	Six Months Ended June 30,
	2013		2012
Collaborator:
Bristol-Myers Squibb	73	%	59	%
Merck	—	%	41	%
Pharmacy:
Diplomat Specialty Pharmacy	26	%	—	%

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Exelixis, Inc. (“Exelixis,” “we,” “our” or “us”) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. We are focusing our proprietary resources and development and commercialization efforts exclusively on COMETRIQ^® (cabozantinib), our wholly-owned inhibitor of multiple receptor tyrosine kinases. On November 29, 2012, the U.S. Food and Drug Administration approved COMETRIQ for the treatment of progressive, metastatic medullary thyroid cancer (“MTC”), in the United States, where it became commercially available in late January 2013. Cabozantinib is being evaluated in a variety of other cancer indications through a broad development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer, a phase 3 pivotal trial in metastatic renal cell cancer and an additional phase 3 pivotal trail in metastatic hepatocellular cancer that we plan to initiate later in 2013. We believe COMETRIQ has the potential to be a high-quality, broadly-active and differentiated anti-cancer agent that can make a meaningful difference in the lives of patients. Our objective is to develop COMETRIQ into a major oncology franchise, and we believe that the approval of COMETRIQ for the treatment of progressive, metastatic MTC provides us with the opportunity to establish a commercial presence in furtherance of this objective. We have also established a portfolio of other novel compounds that we believe have the potential to address serious unmet medical needs. Many of these compounds are being developed by partners as part of collaborations, at no cost to us but with significant retained economics to us in the event these compounds are commercialized. As disclosed on ClinicalTrials.gov (NCT01689519), a phase 3 clinical trial for one of these compounds, cobimetinib (GDC-0973/XL518), which we out-licensed to Genentech, Inc. (a wholly-owned member of the Roche Group), was initiated on November 1, 2012.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the period presented have been included. Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31^st. Fiscal year 2012, a 52-week year, ended on December 28, 2012, and fiscal year 2013, a 52-week year, will end on December 27, 2013. For convenience, references in this report as of and for the fiscal quarters ended June 29, 2012 and June 28, 2013, and as of the fiscal year ended December 28, 2012, are indicated as ended June 30, 2012, June 30, 2013, and December 31, 2012, respectively. Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013 or for any future period. These financial statements and notes should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2012, included in our Annual Report on Form 10-K filed with the SEC on February 21, 2013.
Fiscal Period, Policy	Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31^st.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, inventory valuation, valuation of long-lived assets, certain accrued liabilities, share-based compensation and the valuation of the debt and equity components of our convertible debt at issuance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Inventory	Inventory We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but rather are expensed as research and development costs. When regulatory approval is obtained, we begin capitalization of inventory related costs. We received regulatory approval for our first product, COMETRIQ, on November 29, 2012. Inventory is valued at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.
Revenue Recognition	Revenue Recognition We recognize revenue from the sale of COMETRIQ and from license fees and milestones earned on research and collaboration arrangements. See “Note 1 - Organization and Summary of Significant Accounting Policies” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a description of our policies for revenue recognition on research and collaboration agreements. We did not enter into any new collaboration agreements during the three and six months ended June 30, 2013. See “Note 2 - Research and Collaboration Agreements” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 for a description of our existing collaboration agreements. Net Product Revenues We recognize revenue when it is both realized or realizable and earned, meaning persuasive evidence of an arrangement exists, delivery has occurred, title has transferred, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured. For product sales in the United States, this generally occurs upon shipment of the product to the patient. For product sales in Europe, this occurs when our distribution partner, Sobi, has accepted the product. We sell our product, COMETRIQ, in the United States to a specialty pharmacy that benefits from customer incentives and has a right of return. We have a limited sales history and cannot reliably estimate expected returns of the product nor the discounts and rebates due to payors at the time of shipment to the specialty pharmacy. Accordingly, upon shipment to the specialty pharmacy, we record deferred revenue on our Consolidated Balance Sheets. We recognize revenue when the specialty pharmacy provides the product to a patient based on the fulfillment of a prescription. We record revenue using an analysis of prescription data from our specialty pharmacy to ascertain the date of shipment and the payor mix. This approach is frequently referred to as the “sell-through” revenue recognition model. Once the prescription has been provided to the patient, it is not subject to return unless the product is damaged. Product sales to Sobi are not subject to customer incentives, rights of return or discounts and allowances. We record revenue at the time Sobi has accepted the product, a method also known as the “sell-in” revenue recognition model. Product Sales Discounts and Allowances We calculate gross product revenues based on the price that we charge our United States specialty pharmacy and our European distribution partner, Sobi. We estimate our net product revenues by deducting from our gross product revenues (a) trade allowances, such as discounts for prompt payment, (b) estimated government rebates and chargebacks, and (c) estimated costs of patient assistance programs. We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. These discounts and allowances apply only to gross product revenues earned in the United States. Customer Credits: The United States specialty pharmacy receives a discount of 2% for prompt payment. We expect this specialty pharmacy will earn 100% of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized. Mandated Rebates: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payor data received from the United States specialty pharmacy. Rebates are generally invoiced by the payor and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s shipments to patients, plus an accrual balance for known prior quarter’s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment. Chargebacks: Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The United States specialty pharmacy, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy and the discounted price paid to the specialty pharmacy by the customer. The allowance for chargebacks is based on sales to contracted customers. Medicare Part D Coverage Gap: In the United States, the Medicare Part D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part D coverage gap are based in part on third party market research data and on customer and payor, data received from the United States specialty pharmacy. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment. Co-payment Assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by our United States specialty pharmacy. Patient Assistance Program We provide COMETRIQ at no cost to eligible patients who have no insurance or are otherwise unable to pay for our product through our Patient Assistance Program (“PAP”). We record the cost of the product as a selling, general and administrative expense at the time the product is designated as PAP inventory.
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold is related to our product revenues and consists primarily of indirect labor costs, a 3% royalty we are required to pay GlaxoSmithKline and direct logistics costs. A significant portion of the manufacturing costs for current product sales were incurred prior to regulatory approval of COMETRIQ for the treatment of progressive, metastatic MTC and, therefore, are expensed as research and development costs as incurred, rather than capitalized as inventory. In accordance with our 2002 collaboration agreement with GlaxoSmithKline, we are required to pay GlaxoSmithKline a 3% royalty on the Net Sales of any product incorporating cabozantinib, including COMETRIQ. Net Sales is defined in the collaboration agreement generally as the gross invoiced sales price less customer credits, rebates, chargebacks, shipping costs, customs duties, and sales tax and other similar tax payments we are required to make.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2013, Accounting Standards Codification Topic 220, Comprehensive Income was amended to require additional information about amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning January 1, 2013, and will provide the additional information when such reclassifications occur. The amendment did not have a material effect on our consolidated financial statements.

Restructurings (Tables)

6 Months Ended

Jun. 30, 2013

Restructuring Charges [Abstract]

Summary Of Components Of Restructuring Liability

The components and changes of these liabilities during the six months ended June 30, 2013 and for the period from inception of the restructuring activities through the year ended December 31, 2012 are summarized in the following table (in thousands):



	Employee Severance And Other Benefits			Facility Charges			Asset Impairment			Legal and Other Fees			Total
Restructuring (credit) charge	$	17,677		$	11,814		$	3,173		$	80		$	32,744
Cash payments	(10,528		)	(3,739		)	—			(10		)	(14,277		)
Adjustments or non-cash credits	(1,626		)	613			(3,341		)	—			(4,354		)
Proceeds from sale of assets	—			—			168			—			168
Restructuring liability as of December 31, 2010	5,523			8,688			—			70			14,281
Restructuring (credit) charge	2,566			8,480			(907		)	(3		)	10,136
Cash payments	(7,366		)	(3,469		)	—			(16		)	(10,851		)
Adjustments or non-cash credits	(717		)	222			(619		)	—			(1,114		)
Proceeds from sale of assets	—			—			1,526			—			1,526
Restructuring liability as of December 31, 2011	6			13,921			—			51			13,978
Restructuring (credit) charge	970			8,276			(47		)	(28		)	9,171
Cash payments	(965		)	(5,299		)	—			(3		)	(6,267		)
Adjustments or non-cash credits including stock compensation expense	(11		)	2,304			(891		)	—			1,402
Proceeds from sale of assets	—			—			938			—			938
Restructuring liability as of December 31, 2012	—			19,202			—			20			19,222
Restructuring charge	263			465			—			—			728
Cash payments	—			(3,955		)	—			—			(3,955		)
Adjustments or non-cash credits	(49		)	(73		)	—			—			(122		)
Restructuring liability as of June 30, 2013	$	214		$	15,639		$	—		$	20		$	15,873

Cash and Investments Cash and Investments (Tables)

6 Months Ended

Jun. 30, 2013

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-Sale Securities

The following table summarizes cash and cash equivalents, investments, and restricted cash and investments by balance sheet line item as of June 30, 2013 and December 31, 2012 (in thousands):



	June 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
As reported:
Cash and cash equivalents	$	131,773	$	1	$	—		$	131,774
Short-term investments	220,254		62		(118		)	220,198
Short-term restricted cash and investments	12,193		21		—			12,214
Long-term investments	138,400		7		(282		)	138,125
Long-term restricted cash and investments	21,910		46		—			21,956
Total cash and investments	$	524,530	$	137	$	(400	)	$	524,267



	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
As reported:
Cash and cash equivalents	$	170,070	$	—	$	(1	)	$	170,069
Short-term investments	241,391		46		(66		)	241,371
Short-term restricted cash and investments	12,242		4		—			12,246
Long-term investments	182,407		28		(124		)	182,311
Long-term restricted cash and investments	27,943		21		—			27,964
Total cash and investments	$	634,053	$	99	$	(191	)	$	633,961

Summary of Cash and Investments by Security Type

The following table summarizes our cash equivalents and investments by security type as of June 30, 2013 and December 31, 2012 (in thousands):



	June 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Cash and money market funds	$	62,054	$	—	$	—		$	62,054
Commercial paper	87,217		—		(2		)	87,215
Corporate bonds	273,748		42		(396		)	273,394
U.S. Treasury and government sponsored enterprises	89,493		94		—			89,587
Municipal bonds	12,018		1		(2		)	12,017
Total cash and investments	$	524,530	$	137	$	(400	)	$	524,267



	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Cash and money market funds	$	81,744	$	2	$	—		$	81,746
Commercial paper	167,223		8		—			167,231
Corporate bonds	222,106		30		(187		)	221,949
U.S. Treasury and government sponsored enterprises	132,933		59		(1		)	132,991
Municipal bonds	30,047		—		(3		)	30,044
Total cash and investments	$	634,053	$	99	$	(191	)	$	633,961

Summary of Available-for-Sale Securities by Contractual Maturity

The following summarizes the fair value of securities classified as available-for-sale by contractual maturity as of June 30, 2013 (in thousands):



	Mature within One Year		After One Year through Two Years		Fair Value
Money market funds	$	58,934	$	—	$	58,934
Commercial paper	87,215		—		87,215
Corporate bonds	176,441		96,953		273,394
U.S. Treasury and government sponsored enterprises	71,357		18,230		89,587
Municipal bonds	12,017		—		12,017
Total	$	405,964	$	115,183	$	521,147

Inventory Inventory (Tables)

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):



	June 30, 2013		December 31, 2012
Raw materials	$	75	$	—
Work in process	537		—
Finished goods	69		—
Total	$	681	$	—

Debt (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Schedule Of Debt

The amortized carrying amount of our debt consists of the following (in thousands):



	June 30, 2013			December 31, 2012
Convertible Senior Subordinated Notes due 2019	$	157,357		$	149,800
Secured Convertible Notes due 2015	95,102			100,676
Silicon Valley Bank term loan	80,000			80,000
Silicon Valley Bank line of credit	3,678			5,260
Total debt	336,137			335,736
Less: current portion	(12,546		)	(13,170		)
Long-term debt	$	323,591		$	322,566

Summary Of The Liability Component Of The 2019 Notes

The following is a summary of the liability component of the 2019 Notes as of June 30, 2013 (in thousands):



	June 30, 2013
Net carrying amount of the liability component	$	157,357
Unamortized discount of the liability component	130,143
Face amount of the 2019 Notes	$	287,500

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Fair Value Measurements Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Of Financial Assets Measured On A Recurring Basis

The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):



	June 30, 2013
	Level 1		Level 2		Total
Money market funds	$	58,934	$	—	$	58,934
Commercial paper	2,997		84,218		87,215
Corporate bonds	7,013		266,381		273,394
U.S. Treasury and government sponsored enterprises	30,444		59,143		89,587
Municipal bonds	—		12,017		12,017
Total	$	99,388	$	421,759	$	521,147



	December 31, 2012
	Level 1		Level 2		Total
Money market funds	$	76,050	$	—	$	76,050
Commercial paper	—		167,231		167,231
Corporate bonds	—		221,949		221,949
U.S. Treasury and government sponsored enterprises	—		132,991		132,991
Municipal bonds	—		30,044		30,044
Total	$	76,050	$	552,215	$	628,265

Schedule Of Estimated Fair Value Of Outstanding Debt

The estimated fair values of our financial instruments that are carried at amortized cost for which it is practicable to determine a fair value were as follows (in thousands):



	June 30, 2013				December 31, 2012
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Convertible Senior Subordinated Notes due 2019	$	157,357	$	279,939	$	149,800	$	280,111
Silicon Valley Bank term loan	$	80,000	$	79,767	$	80,000	$	79,542
Silicon Valley Bank Line of Credit	$	3,678	$	3,676	$	5,260	$	5,253

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2013

Share-based Compensation [Abstract]

Schedule Of Allocated Employee Stock-Based Compensation Expenses

We recorded and allocated employee stock-based compensation expenses for our equity incentive plans and our 2000 Employee Stock Option Plan (“ESPP”) as follows (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Research and development expense	$	1,553	$	1,025	$	2,960	$	2,232
Selling, general and administrative expense	1,370		950		2,638		2,047
Total employee stock-based compensation expense	$	2,923	$	1,975	$	5,598	$	4,279

Schedule Of Fair Value Of Employee Share-Based Payments Awards Estimated Using The Assumptions And Weighted Average Fair Values

The fair value of employee stock option awards and ESPP purchases was estimated using the following assumptions and weighted average fair values:



	Stock Options
	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Weighted average grant-date fair value	$	2.56		$	2.68		$	2.52		$	2.75
Risk-free interest rate	0.98		%	1.00		%	0.92		%	1.00		%
Dividend yield	—		%	—		%	—		%	—		%
Volatility	62		%	65		%	62		%	65		%
Expected life	5.6 years			6.0 years			5.5 years			5.8 years



	Employee Stock Purchase Plan
	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Weighted average grant-date fair value	$	1.65		$	1.58		$	1.63		$	2.34
Risk-free interest rate	0.12		%	0.16		%	0.13		%	0.08		%
Dividend yield	—		%	—		%	—		%	—		%
Volatility	67		%	68		%	67		%	68		%
Expected life	0.5 years			0.5 years			0.5 years			0.5 years

Summary Of All Stock Option Activity

A summary of all stock option activity for the six months ended June 30, 2013 is presented below (dollars in thousands, except per share amounts):



	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Options outstanding at December 31, 2012	18,448,550		$	6.85
Granted	851,130		$	4.65
Exercised	(3,884	)	$	4.42
Forfeited	(586,964	)	$	6.47
Options outstanding at June 30, 2013	18,708,832		$	6.76	4.35	$	108
Exercisable at June 30, 2013	13,175,393		$	7.31	3.63	$	94

Summary Of All RSU Activity

A summary of all restricted stock unit (“RSU”) activity for the six months ended June 30, 2013 is presented below (dollars in thousands, except per share amounts):



	Shares		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Awards outstanding at December 31, 2012	1,294,621		$	6.07
Awarded	87,710		$	4.74
Released	(153,747	)	$	7.34
Forfeited	(15,208	)	$	5.74
Awards outstanding at June 30, 2013	1,213,376		$	5.82	1.55	$	5,509

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Schedule Of Reconciliation Of Basic And Diluted Net Income (Loss) Per Share

The following table sets forth a reconciliation of basic and diluted net loss per share (in thousands, except per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Numerator:
Net loss	$	(62,161	)	$	(36,487	)	$	(106,890	)	$	(62,638	)
Denominator:
Shares used in computing basic and diluted net loss per share	183,981			148,654			183,861			145,297
Net loss per share, basic and diluted	$	(0.34	)	$	(0.25	)	$	(0.58	)	$	(0.43	)

Schedule Of Potential Shares Of Common Stock Not Included In Computation Of Diluted Net Loss Per Share

The following table sets forth potential shares of common stock that are not included in the computation of diluted net loss per share because, to do so would be anti-dilutive (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2013	2012	2013	2012
Convertible debt	54,123	—	54,123	—
Outstanding stock options, unvested RSUs and ESPP contributions	18,147	17,477	18,007	16,226
Warrants	1,441	1,441	1,441	1,441
Total potentially dilutive shares	73,711	18,918	73,571	17,667

Concentrations of Credit Risk (Tables)

6 Months Ended

Jun. 30, 2013

Risks and Uncertainties [Abstract]

Schedules of collaborators that represent 10% or more of total revenues



	Six Months Ended June 30,
	2013		2012
Collaborator:
Bristol-Myers Squibb	73	%	59	%
Merck	—	%	41	%
Pharmacy:
Diplomat Specialty Pharmacy	26	%	—	%

Organization and Summary of Significant Accounting Policies (Details)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2013 phase	Jun. 30, 2013 phase segment	Dec. 31, 2012	Dec. 31, 2011
Operations [Line Items]
Number of Operating Segments \| segment		1
Annual Operating Cycle		P52W	P52W
Sales Revenue, Percent Discount for Prompt Payment		2.00%
Glaxo Smith Kline [Member]
Operations [Line Items]
Percent of royalty on net sale		3.00%
Minimum [Member]
Operations [Line Items]
Annual Operating Cycle		P52W
Maximum [Member]
Operations [Line Items]
Annual Operating Cycle		P53W
Geographic Concentration Risk [Member] \| Revenue [Member] \| UNITED STATES
Operations [Line Items]
Concentration Risk, Percentage	93.00%	95.00%	100.00%	100.00%
COMETRIQ [Member]
Operations [Line Items]
Number of Phases in Process \| phase	2	2

Restructurings (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended			42 Months Ended
Restructurings (Narrative) (Details) $ in Thousands	Jun. 30, 2013 USD ($) employee	Jun. 30, 2012 USD ($)	Jun. 30, 2013 USD ($) employee	Jun. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Jun. 30, 2013 USD ($) employee
Restructuring Cost and Reserve [Line Items]
Aggregate reduction in headcount \| employee	429		429					429
Aggregate restructuring charges	$ 609	$ 1,166	$ 728	$ 971
Proceeds from sale of property and equipment			0	859
Expected additional payment for restructuring			2,500
Restructuring Reserve, Settled with Cash								$ 32,700
Total Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges			728		$ 9,171	$ 10,136	$ 32,744	52,800
Proceeds from sale of property and equipment					938	1,526	168
Restructuring Reserve	15,873		15,873		19,222	13,978	14,281	15,873
Restructuring Reserve, Settled with Cash			3,955		6,267	10,851	14,277
Restructuring Reserve, Cash Settlement Net of Proceeds	1,500	$ 1,300	4,000	$ 2,300
Termination Benefits and Facility Charges [Member]
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges			1,000
Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges								21,500
Expected additional payment for restructuring			300
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges			465		8,276	8,480	11,814	29,000
Proceeds from sale of property and equipment					0	0	0
Restructuring Reserve	15,639		15,639		19,202	13,921	8,688	15,639
Restructuring Reserve, Settled with Cash			3,955		5,299	3,469	3,739
Asset Impairment [Member]
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges			0		(47)	(907)	3,173	2,200
Proceeds from sale of property and equipment					938	1,526	168	2,600
Restructuring Reserve	$ 0		0		0	0	0	0
Restructuring Reserve, Settled with Cash			$ 0		$ 0	$ 0	$ 0
Legal and Other Fees [Member]
Restructuring Cost and Reserve [Line Items]
Aggregate restructuring charges								$ 100

Restructurings (Summary of Components of Restructuring Liability) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended			42 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jun. 30, 2013
Restructuring Reserve [Roll Forward]
Restructuring charge	$ 609	$ 1,166	$ 728	$ 971
Cash payments								$ (32,700)
Proceeds from sale of assets			0	859
Employee Severance And Other Benefits [Member]
Restructuring Reserve [Roll Forward]
Restructuring liability			0	6	$ 6	$ 5,523
Restructuring charge			263		970	2,566	$ 17,677
Cash payments			0		(965)	(7,366)	(10,528)
Adjustments or non-cash credits			(49)		(11)	(717)	(1,626)
Proceeds from sale of assets					0	0	0
Restructuring liability	214		214		0	6	5,523	214
Facility Charges [Member]
Restructuring Reserve [Roll Forward]
Restructuring liability			19,202	13,921	13,921	8,688
Restructuring charge			465		8,276	8,480	11,814	29,000
Cash payments			(3,955)		(5,299)	(3,469)	(3,739)
Adjustments or non-cash credits			(73)		2,304	222	613
Proceeds from sale of assets					0	0	0
Restructuring liability	15,639		15,639		19,202	13,921	8,688	15,639
Asset Impairment [Member]
Restructuring Reserve [Roll Forward]
Restructuring liability			0	0	0	0
Restructuring charge			0		(47)	(907)	3,173	2,200
Cash payments			0		0	0	0
Adjustments or non-cash credits			0		(891)	(619)	(3,341)
Proceeds from sale of assets					938	1,526	168	2,600
Restructuring liability	0		0		0	0	0	0
Legal And Other Fees [Member]
Restructuring Reserve [Roll Forward]
Restructuring liability			20	51	51	70
Restructuring charge			0		(28)	(3)	80
Cash payments			0		(3)	(16)	(10)
Adjustments or non-cash credits			0		0	0	0
Proceeds from sale of assets					0	0	0
Restructuring liability	20		20		20	51	70	20
Total Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring liability			19,222	$ 13,978	13,978	14,281
Restructuring charge			728		9,171	10,136	32,744	52,800
Cash payments			(3,955)		(6,267)	(10,851)	(14,277)
Adjustments or non-cash credits			(122)		1,402	(1,114)	(4,354)
Proceeds from sale of assets					938	1,526	168
Restructuring liability	$ 15,873		$ 15,873		$ 19,222	$ 13,978	$ 14,281	$ 15,873

Cash and Investments Cash and Investments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2013 USD ($) investment	Dec. 31, 2012 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 524,530	$ 634,053
Gross Unrealized Gains	137	99
Gross Unrealized Losses	(400)	(191)
Fair Value	524,267	633,961
Unrealized loss position	$ 223,300
Number of investments in an unrealized loss position \| investment	104
Unrealized loss position of all securities in years	1 year
Silicon Valley Bank Loan And Security Agreement [Member]
Schedule of Available-for-sale Securities [Line Items]
Collateral balance	$ 85,400	87,000
Cash and cash equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	131,773	170,070
Gross Unrealized Gains	1	0
Gross Unrealized Losses	0	(1)
Fair Value	131,774	170,069
Short-term investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	220,254	241,391
Gross Unrealized Gains	62	46
Gross Unrealized Losses	(118)	(66)
Fair Value	220,198	241,371
Short-term restricted cash and investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,193	12,242
Gross Unrealized Gains	21	4
Gross Unrealized Losses	0	0
Fair Value	12,214	12,246
Long-term investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	138,400	182,407
Gross Unrealized Gains	7	28
Gross Unrealized Losses	(282)	(124)
Fair Value	138,125	182,311
Long-term restricted cash and investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	21,910	27,943
Gross Unrealized Gains	46	21
Gross Unrealized Losses	0	0
Fair Value	21,956	27,964
Cash and money market funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	62,054	81,744
Gross Unrealized Gains	0	2
Gross Unrealized Losses	0	0
Fair Value	62,054	81,746
Money market funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Fair Value	58,934
Mature within One Year	58,934
After One Year through Two Years	0
Commercial paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	87,217	167,223
Gross Unrealized Gains	0	8
Gross Unrealized Losses	(2)	0
Fair Value	87,215	167,231
Mature within One Year	87,215
After One Year through Two Years	0
Corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	273,748	222,106
Gross Unrealized Gains	42	30
Gross Unrealized Losses	(396)	(187)
Fair Value	273,394	221,949
Unrealized loss position	215,200
Mature within One Year	176,441
After One Year through Two Years	96,953
U.S. Treasury and government sponsored enterprises [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	89,493	132,933
Gross Unrealized Gains	94	59
Gross Unrealized Losses	0	(1)
Fair Value	89,587	132,991
Mature within One Year	71,357
After One Year through Two Years	18,230
Municipal bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,018	30,047
Gross Unrealized Gains	1	0
Gross Unrealized Losses	(2)	(3)
Fair Value	12,017	$ 30,044
Mature within One Year	12,017
After One Year through Two Years	0
Investments, excluding cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Fair Value	521,147
Mature within One Year	405,964
After One Year through Two Years	$ 115,183

Inventory Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 75	$ 0
Work in process	537	0
Finished goods	69	0
Total	$ 681	$ 0

Debt (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
Debt (Narrative) (Details) - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Aug. 31, 2012	Aug. 14, 2012	Jun. 30, 2010
Senior Subordinated Notes [Member] \| 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]
Debt Instrument [Line Items]
Debt, interest rate							4.25%
Debt, principal amount	$ 287,500,000		$ 287,500,000			$ 287,500,000
Interest Expense, Debt	7,100,000		14,000,000
Interest Expense, Coupon Interest	3,100,000		6,100,000
Convertible Debt	157,357,000		157,357,000		$ 149,800,000
Amortization of Financing Costs and Discounts	4,000,000		7,900,000
Balance of unamortized closing fees and expenses	4,300,000		4,300,000		4,700,000
Secured Convertible Notes Due June 2015 [Member] \| Deerfield Financing [Member]
Debt Instrument [Line Items]
Debt, principal amount								$ 124,000,000
Interest Expense, Debt	4,000,000	$ 3,900,000	7,900,000	$ 7,700,000
Convertible Debt	114,000,000		114,000,000		124,000,000
Amortization of Financing Costs and Discounts	2,500,000	$ 2,400,000	4,900,000	$ 4,700,000
Balance of unamortized closing fees and expenses	$ 1,800,000		$ 1,800,000		$ 2,300,000

Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Total debt	$ 336,137	$ 335,736
Less: current portion	(12,546)	(13,170)
Long-term debt	323,591	322,566
Senior Subordinated Notes [Member] \| Convertible Senior Subordinated Notes due 2019 [Member]
Debt Instrument [Line Items]
Convertible Debt	157,357	149,800
Secured Debt [Member] \| Deerfield Notes [Member]
Debt Instrument [Line Items]
Convertible Debt	95,102	100,676
Term Loan [Member] \| Silicon Valley Bank term loan and Line of Credit [Member]
Debt Instrument [Line Items]
Silicon Valley Bank term loan	80,000	80,000
Line of Credit [Member] \| Silicon Valley Bank term loan and Line of Credit [Member]
Debt Instrument [Line Items]
Silicon Valley Bank Line of Credit	$ 3,678	$ 5,260

Debt (2019 Notes) (Details) - Senior Subordinated Notes [Member] - 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member] - USD ($)	Jun. 30, 2013	Dec. 31, 2012	Aug. 31, 2012
Debt Instrument [Line Items]
Net carrying amount of the liability component	$ 157,357,000	$ 149,800,000
Unamortized discount of the liability component	130,143,000
Face amount	$ 287,500,000		$ 287,500,000

Fair Value Measurements (Schedule Of Fair Value Of Financial Assets Measured On A Recurring Basis) (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	$ 99,388	$ 76,050
Level 1 [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	58,934	76,050
Level 1 [Member] \| Commercial paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	2,997	0
Level 1 [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	7,013	0
Level 1 [Member] \| U.S. Treasury and government sponsored enterprises [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	30,444	0
Level 1 [Member] \| Municipal bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	0	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	421,759	552,215
Level 2 [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	0	0
Level 2 [Member] \| Commercial paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	84,218	167,231
Level 2 [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	266,381	221,949
Level 2 [Member] \| U.S. Treasury and government sponsored enterprises [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	59,143	132,991
Level 2 [Member] \| Municipal bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	12,017	30,044
Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	521,147	628,265
Estimate of Fair Value, Fair Value Disclosure [Member] \| Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	58,934	76,050
Estimate of Fair Value, Fair Value Disclosure [Member] \| Commercial paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	87,215	167,231
Estimate of Fair Value, Fair Value Disclosure [Member] \| Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	273,394	221,949
Estimate of Fair Value, Fair Value Disclosure [Member] \| U.S. Treasury and government sponsored enterprises [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	89,587	132,991
Estimate of Fair Value, Fair Value Disclosure [Member] \| Municipal bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value of financial assets	$ 12,017	$ 30,044

Fair Value Measurements (Schedule of Estimated Fair Value of Outstanding Debt) (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Carrying Amount [Member] \| Senior Subordinated Notes [Member] \| 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	$ 157,357	$ 149,800
Carrying Amount [Member] \| Term Loan [Member] \| Silicon Valley Bank term loan and Line of Credit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	80,000	80,000
Carrying Amount [Member] \| Line of Credit [Member] \| Silicon Valley Bank term loan and Line of Credit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	3,678	5,260
Fair Value [Member] \| Senior Subordinated Notes [Member] \| 4.25% Convertible Senior Subordinated Notes due August 15, 2019 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	279,939	280,111
Fair Value [Member] \| Term Loan [Member] \| Silicon Valley Bank term loan and Line of Credit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	79,767	79,542
Fair Value [Member] \| Line of Credit [Member] \| Silicon Valley Bank term loan and Line of Credit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Fair Value Disclosure	$ 3,676	$ 5,253

Stock-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, in shares	18,708,832	18,448,550
Performance Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, in shares	755,792
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 13.6
Unrecognized compensation expense, weighted-average period for recognition (in years)	2 years 7 months 20 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 4.9
Unrecognized compensation expense, weighted-average period for recognition (in years)	2 years 8 months 23 days

Stock-Based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	$ 2,923	$ 1,975	$ 5,598	$ 4,279
Research and development expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	1,553	1,025	2,960	2,232
Selling, general and administrative expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total employee stock-based compensation expense	$ 1,370	$ 950	$ 2,638	$ 2,047

Stock-Based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards Estimated Using the Assumptions and Weighted Average Fair Values) (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 2.56	$ 2.68	$ 2.52	$ 2.75
Risk-free interest rate	0.98%	1.00%	0.92%	1.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	62.00%	65.00%	62.00%	65.00%
Expected life	5 years 7 months 13 days	6 years	5 years 5 months 23 days	5 years 9 months
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 1.65	$ 1.58	$ 1.63	$ 2.34
Risk-free interest rate	0.12%	0.16%	0.13%	0.08%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	67.00%	68.00%	67.00%	68.00%
Expected life	6 months	6 months	6 months	6 months

Stock-Based Compensation (Summary of All Stock Option Activity) (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2013 USD ($) $ / shares shares
Shares [Roll Forward]
Options outstanding at beginning of period, Shares \| shares	18,448,550
Granted, Shares \| shares	851,130
Exercised, Shares \| shares	(3,884)
Forfeited, Shares \| shares	(586,964)
Options outstanding at end of period, Shares \| shares	18,708,832
Exercisable at end of period, Shares \| shares	13,175,393
Weighted Average Exercise Price [Roll Forward]
Options outstanding at beginning of period, Weighted Average Exercise Price \| $ / shares	$ 6.85
Granted, Weighted Average Exercise Price \| $ / shares	4.65
Exercised, Weighted Average Exercise Price \| $ / shares	4.42
Forfeited, Weighted Average Exercise Price \| $ / shares	6.47
Options outstanding at end of period, Weighted Average Exercise Price \| $ / shares	6.76
Exercisable at end of period, Weighted Average Exercise Price \| $ / shares	$ 7.31
Options outstanding at end of period, Weighted Average Remaining Contractual Term	4 years 4 months 6 days
Exercisable at end of period, Weighted Average Remaining Contractual Term	3 years 7 months 17 days
Options outstanding at end of period, Aggregate Intrinsic Value, in dollars \| $	$ 108
Exercisable at end of period, Aggregate Intrinsic Value, in dollars \| $	$ 94

(Summary of All RSU Activity) (Details) - Restricted Stock Units (RSUs) [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2013 USD ($) $ / shares shares
Shares [Roll Forward]
RSUs outstanding at beginning of period, Shares \| shares	1,294,621
Awarded, Shares \| shares	87,710
Released, Shares \| shares	(153,747)
Forfeited, Shares \| shares	(15,208)
RSUs outstanding at end of period, Shares \| shares	1,213,376
Weighted Average Grant DateFair Value [Roll Forward]
RSUs outstanding at beginning of period, Weighted Average Grant Date Fair Value \| $ / shares	$ 6.07
Awarded, Weighted Average Grant Date Fair Value \| $ / shares	4.74
Released, Weighted Average Grant Date Fair Value \| $ / shares	7.34
Forfeited, Weighted Average Grant Date Fair Value \| $ / shares	5.74
RSUs outstanding at end of period, Weighted Average Grant Date Fair Value \| $ / shares	$ 5.82
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	1 year 6 months 18 days
RSUs outstanding at end of period, Aggregate Intrinsic Value, in dollars \| $	$ 5,509

Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss, in dollars	$ (62,161)	$ (36,487)	$ (106,890)	$ (62,638)
Shares used in computing basic and diluted net loss per share	183,981	148,654	183,861	145,297
Net loss per share, basic and diluted, in dollars per share	$ (0.34)	$ (0.25)	$ (0.58)	$ (0.43)
Potentially dilutive shares	73,711	18,918	73,571	17,667
Convertible debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares	54,123	0	54,123	0
Outstanding stock options, unvested RSUs and ESPP contributions [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares	18,147	17,477	18,007	16,226
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive shares	1,441	1,441	1,441	1,441

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Concentrations of Credit Risk (Details) - Revenue from Rights Concentration Risk [Member]	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Bristol-Myers Squibb [Member] \| Revenue, Rights Granted [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	73.00%	59.00%
Merck [Member] \| Revenue, Rights Granted [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		41.00%
Diplomat Specialty Pharmacy [Member] \| Sales Revenue, Goods, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	26.00%